ECOVAL ® Betamethasone

ECOVAL ® is a drug based on betamethasone valerate

THERAPEUTIC GROUP: Non-associated corticosteroids, dermatological preparations

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications ECOVAL ® Betamethasone

ECOVAL ® is indicated in the treatment of cutaneous inflammatory manifestations sensitive to corticosteroids such as dermatitis, lichen, psoriasis, neurodermatitis, eczema, pityriasis and alopecia areata.

Mechanism of action ECOVAL ® Betamethasone

Betamethasone, the active ingredient of ECOVAL ®, is a synthetic corticosteroid successfully used in topical therapy of inflammatory and allergic skin diseases.

The excellent pharmacokinetic properties in fact allow this topically applied molecule to penetrate the various epithelial cell layers, carrying out its own anti-inflammatory, anti-edematous and antiallergic biological action.

These properties, evidently linked to Betamethasone's ability to reprogram gene expression by reducing the synthesis of inflammatory mediators, quickly guarantee a rapid remission of the complained symptomatology, significantly improving the clinical condition of the affected patient.

Everything is also well tolerated and safe from the clinical point of view, given the negligible systemic absorption of the active ingredient.

Studies carried out and clinical efficacy

BETAMETASONE AND ATOPIC DERMATITIS

Allergy. 2012 Mar; 67 (3): 413-23. doi: 10.1111 / j.1398-9995.2011.02747.x. Epub 2011 Dec 6.

Work that reaffirms the clinical utility of corticosteroids in improving the clinical situation of lesions present during atopic dermatitis, emphasizing the ability of these drugs to completely reprogram gene expression.

THE CLINICAL EFFECTIVENESS OF BETAMETASONE IN THE TREATMENT OF PSORIASIS

Curr Med Res Opin. 2011 Jan; 27 (1): 197-203. doi: 10.1185 / 03007995.2010.540985. Epub 2010 Dec 13.

Study demonstrating the clinical efficacy of topical treatment combined with Calcipotriol - Betamethasone in patients suffering from psoriasis of the body and scalp.

SIMVASTATINE IMPROVES THE THERAPEUTIC EFFECTIVENESS OF BETAMETASONE IN PSORIASIS

Niger J Med. 2010 Jan-Mar; 19 (1): 58-61.

Very interesting clinical trial that demonstrates how the addition of oral Simvastatin can significantly improve the therapeutic efficacy of topical Betamethasone in the treatment of psoriasis, also reducing the cardiovascular risk.

Method of use and dosage

ECOVAL ®

Cream, skin emulsion and 0.1% Betamethasone ointment;

0.05% cutaneous solution of Betamethasone.

Also in this case the choice of the pharmaceutical format and the definition of the therapeutic scheme is up to the doctor after evaluating the patient's clinical conditions.

Generally it is recommended to apply the appropriate quantity of medicine 2-3 times a day in the initial phases of the treatment to gradually decrease with the regression of the symptoms.

The ointment is indicated for the treatment of dry and scaly dermatoses, the cream for localized lesions and the skin emulsion for hairy skin lesions.

Warnings ECOVAL ® Betamethasone

Therapy with ECOVAL ® must necessarily be preceded by a careful medical examination in order to clarify the origin of the inflammatory manifestations and any prescriptive appropriateness.

In order to limit the incidence of side effects and maximize therapeutic efficacy at the same time, the patient receiving ECOVAL ® should:

avoid contact of the drug with eyes and mucous membranes;
avoid using the occlusive bandage;
avoid applying the medicine on large and severely damaged skin areas;
avoid prolonged use of the drug;
clean hands thoroughly after each application;
avoid direct exposure to ultraviolet radiation.

Maximum caution should also be reserved for elderly patients or those suffering from severe liver and kidney diseases.

PREGNANCY AND BREASTFEEDING

The aforementioned contraindications to the use of ECOVAL ® generally extend also to pregnancy and the subsequent period of breastfeeding, given the absence of clinical trials able to better characterize the safety profile of topical Betamethasone for fetal health and of the infant.

Interactions

Despite the fact that the active principle is not absorbed in clinically relevant quantities, it should be remembered that the simultaneous intake of cytochrome inhibitor drugs could increase the patient's systemic exposure to the active ingredient.

Contraindications ECOVAL ® Betamethasone

The use of ECOVAL ® is contraindicated in patients who are hypersensitive to the active substance or to one of its excipients, in patients under the age of 1 year and in patients suffering from serious bacterial and viral infections such as tuberculous, lactic and viral processes, acne rosacea, perioral dermatitis, perianal and genital itching and skin ulcers.

Undesirable effects - Side effects

The use of ECOVAL ®, especially when prolonged over time, could facilitate the appearance of local adverse reactions such as burning, erythema, dermatitis, hypertrichosis, dry skin, skin atrophy and other dermatological manifestations.

Systemic adverse reactions are decidedly more rare.